Format

Send to

Choose Destination
Facts Views Vis Obgyn. 2011;3(2):109-20.

Progesterone for Symptomatic Perimenopause Treatment - Progesterone politics, physiology and potential for perimenopause.

Author information

1
Endocrinology, University of British Columbia, and Vancouver Coastal Health Research. Institute, Vancouver, Canada V5Z 1M9. Scientific Director, Centre for Menstrual Cycle and Ovulation Research ( www.cemcor.ubc.ca ).

Abstract

Perimenopause, women's normal midlife reproductive transition, is highly symptomatic for about 20% of women who are currently inaccurately counseled and inappropriately treated with oral contraceptives, menopausal hormone therapy or hysterectomy. About 80% of perimenopausal women experience vasomotor symptoms (VMS), 25% have menorrhagia, and about 10% experience mastalgia. The majority of women describe varying intensities of sleep, -coping or mood difficulties. Women are more symptomatic because common knowledge inaccurately says that estradiol (E2) levels are dropping/deficient. Evidence shows that with disturbed brain-ovary feedbacks, E2 levels average 26% higher and soar erratically - some women describe feeling pregnant! Also, ovulation and progesterone (P4) levels become insufficient or absent. The most symptomatic women have higher E2 and lower P4 levels. Because P4 and E2 complement/counterbalance each other's tissue effects, oral micronized P4 (OMP4 300 mg at -bedtime) is a physiological therapy for treatment-seeking, symptomatic perimenopausal women. Given cyclically (cycle d 14-27, or 14 on/off) in menstruating midlife women, OMP4 decreases cyclic VMS, improves sleep and premenstrual mastalgia. Menorrhagia is treated with ibuprofen 200mg/6h plus OMP4 cycle d 4-28. For insulin resistance, metformin plus cyclic or daily OMP4 decreases insulin resistance and weight gain. Non-responsive migraines need daily OMP4 plus usual therapies. VMS and insomnia in late perimenopause respond to daily OMP4. In summary, OMP4 is a physiology-based therapy that improves sleep, treats VMS, does not increase breast proliferation or cancer risk, increases bone formation and has beneficial cardiovascular effects. A controlled trial is testing OMP4 for perimenopausal VMS - more evidence-based data are needed.

KEYWORDS:

Perimenopause; anovulation; asomotor symptoms; breast cancer; cardiovascular disease; estradiol levels; estradiol-progesterone tissue interactions; feminism; history; infertility; insulin resistance; mastalgia; menorrhagia; midlife women; migraine headaches; nausea; night sweats; oral micronized progesterone; osteoporosis; ovulatory disturbances; rapid bone loss; self-actualization; short luteal phase; sleep disturbance; treatment; ­progesterone levels

PMID:
24753856
PMCID:
PMC3987489

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center